Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Acadia to Present Phase 2 Remlifanserin Data in Alzheimer's Psychosis at CTAD 2026

By Public Technologies
  • Acadia Pharmaceuticals will present Phase 2 remlifanserin findings in Alzheimer's disease psychosis at CTAD in Boston, November 16-19, 2026.
  • The ongoing RADIANT trial's efficacy and safety findings are scheduled for an oral presentation November 17 at 9:35 a.m. ET.
  • A separate poster will examine biomarker heterogeneity in clinically diagnosed Alzheimer's disease psychosis patients negative for amyloid proteinopathy and p-Tau217.
  • The poster presentation is scheduled for November 18, from 7:15 a.m. to 5:30 p.m. ET.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611091605BIZWIRE_USPR_____20261109_BW488285) on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.